Scandinavian Medical Solutions (One-pager): The foundation is now built for the next growth phase
Yesterday, Scandinavian Medical Solutions reported its 2023/24 results and announced its new 2024/25 guidance. The 2023/24 results were within the company's guidance, and the new guidance ranges for 2024/25 correspond to between 6-19% revenue growth and an EBITDA margin between 9-12%.
After investments in 2023/24, including in the organization and infrastructure, the US subsidiary, and its Aftersales & Parts and Rental business areas, the foundation is now built for the next growth phase.
We have updated our investment case one-pager following the 2023/24 results, new 2024/25 guidance, and recent news. Besides an overview of financials and valuation multiples, the investment case one-pager introduces Scandinavian Medical Solutions and highlights key investment reasons and risks.
Earlier today, Scandinavian Medical Solutions' CEO Jens Hvid Paulsen and Head of Sales Martin Lind presented the 2023/24 report and new expectations in an online live event (in Danish). Watch the presentation here: https://www.inderes.dk/videos/scandinavian-medical-solutions-praesentation-af-arsrapporten-202324
Disclaimer: HC Andersen Capital receives payment from Scandinavian Medical Solutions for a Digital IR/Corporate Visibility subscription agreement. /Kasper Lihn 15:00, 21 November 2024.
Sisäänkirjautuminen vaadittu
Tämä sisältö on näkyvissä vain sisäänkirjautuneille käyttäjille
Scandinavian Medical Solutions
Scandinavian Medical Solutions is a Danish-based trading company specialized in purchase and resale of used diagnostic imaging equipment such as CT scanners and MR scanners of high quality. Scandinavian Medical Solutions is specialized in offering flexible solutions for customers with specific demands, which is often a better and cheaper alternative to a new and more expensive produced OEM-equipment. Scandinavian Medical Solutions was founded in 2018, and the company has been listed at Nasdaq First North in Denmark since November 2021.
Lue lisää yhtiösivulla